AP314A - "Heteroaryl amides as novel acetylcholinesterase inhibitors" - Google Patents

"Heteroaryl amides as novel acetylcholinesterase inhibitors" Download PDF

Info

Publication number
AP314A
AP314A APAP/P/1992/000421A AP9200421A AP314A AP 314 A AP314 A AP 314A AP 9200421 A AP9200421 A AP 9200421A AP 314 A AP314 A AP 314A
Authority
AP
ARIPO
Prior art keywords
propanone
phenylmethyl
alkyl
piperidinyl
phenyl
Prior art date
Application number
APAP/P/1992/000421A
Other languages
English (en)
Other versions
AP9200421A0 (en
Inventor
Yuhpyng Liang Chen
Arthur A Nagel
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AP9200421A0 publication Critical patent/AP9200421A0/xx
Application granted granted Critical
Publication of AP314A publication Critical patent/AP314A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Control Of El Displays (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
APAP/P/1992/000421A 1991-10-03 1992-09-07 "Heteroaryl amides as novel acetylcholinesterase inhibitors" AP314A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77128391A 1991-10-03 1991-10-03

Publications (2)

Publication Number Publication Date
AP9200421A0 AP9200421A0 (en) 1992-10-31
AP314A true AP314A (en) 1994-02-04

Family

ID=25091318

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1992/000421A AP314A (en) 1991-10-03 1992-09-07 "Heteroaryl amides as novel acetylcholinesterase inhibitors"

Country Status (36)

Country Link
US (4) US5574046A (pl)
EP (1) EP0606248B1 (pl)
JP (1) JP2546785B2 (pl)
KR (1) KR0170458B1 (pl)
CN (1) CN1035615C (pl)
AP (1) AP314A (pl)
AT (1) ATE235490T1 (pl)
AU (1) AU667053B2 (pl)
BG (1) BG61727B1 (pl)
BR (1) BR9206577A (pl)
CA (1) CA2119647C (pl)
CZ (1) CZ290807B6 (pl)
DE (2) DE9290112U1 (pl)
DK (1) DK0606248T3 (pl)
EG (1) EG21481A (pl)
ES (1) ES2193137T3 (pl)
FI (1) FI116939B (pl)
HU (1) HU225049B1 (pl)
IL (1) IL103274A (pl)
IS (1) IS1745B (pl)
MA (1) MA22672A1 (pl)
MX (1) MX9205678A (pl)
NO (1) NO308533B1 (pl)
NZ (1) NZ244601A (pl)
OA (1) OA09895A (pl)
PH (1) PH31290A (pl)
PL (3) PL171669B1 (pl)
PT (1) PT100917B (pl)
RO (1) RO112868B1 (pl)
RU (1) RU2100357C1 (pl)
SG (1) SG52618A1 (pl)
TW (1) TW263504B (pl)
UA (1) UA41290C2 (pl)
UY (1) UY23484A1 (pl)
WO (1) WO1993007140A1 (pl)
ZA (1) ZA927589B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
EP1604653A1 (en) 1998-09-30 2005-12-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
US20050215614A1 (en) * 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
AU2005244867A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
EP1600447A1 (en) * 2004-05-28 2005-11-30 Neuropharma S.A.U. Butyrylcholinesterase selective inhibitors
UY28945A1 (es) 2004-06-09 2006-01-31 Glaxo Group Ltd Derivados de pirrolopiridina
JP2008525439A (ja) * 2004-12-23 2008-07-17 ボイジャー・ファーマシューティカル・コーポレーション アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはnmdaレセプターアゴニスト
CN1808106B (zh) * 2005-01-21 2010-11-24 中国科学院上海药物研究所 一种用核磁共振筛选乙酰胆碱酯酶抑制剂的方法
CN102177436B (zh) 2008-08-12 2015-05-13 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
CN101503414B (zh) * 2009-03-04 2013-10-30 沈阳药科大学 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
DK2482815T3 (en) 2009-10-02 2018-06-06 Avexxin As ANTI-INFLAMMATORY 2-OXOTHIAZOLES AND 2-OXOOXAZOLES
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
SG191399A1 (en) 2011-01-10 2013-08-30 Zinfandel Pharmaceuticals Inc Methods and drug products for treating alzheimer's disease
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN110128370A (zh) 2013-01-29 2019-08-16 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
CN103333163A (zh) * 2013-07-09 2013-10-02 广州中医药大学 一种苯并呋喃类衍生物及其制备方法和应用
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CN107141266B (zh) * 2017-06-28 2019-04-09 佳木斯大学附属第一医院 一种用于治疗阿尔茨海默病的杂环化合物及其制备方法
CN115466211B (zh) * 2022-06-09 2024-02-23 中国人民解放军空军军医大学 一种n-苯基喹啉-4-胺类化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288563A1 (en) * 1986-09-30 1988-11-02 Eisai Co., Ltd. Cyclic amine derivatives
EP0351282A1 (fr) * 1988-07-12 1990-01-17 Synthelabo Dérivés de (hydroxy-1 pipéridinyl-2 alkyl)indolones-2, quinoléinones-2, benzo[b]azépinones-2, benzimidazolones-2 et quinazolinones-2, leur préparation et leur application en thérapeutique
EP0441517A2 (en) * 1990-02-08 1991-08-14 Pfizer Inc. Tricyclic amines as novel cholinesterase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1068259B (pl) * 1954-04-28 1959-11-05
FR2334358A1 (fr) * 1975-12-12 1977-07-08 Sogeras Nouveaux medicaments derives de l'indole
US4122265A (en) * 1976-05-21 1978-10-24 Hoffmann-La Roche Inc. Derivatives of 3-phenylisoindole-1-carboxylic acid
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
GB8615562D0 (en) * 1986-06-25 1986-07-30 Maggioni Farma Aminoalcohols
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
IT1226100B (it) * 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物
US5064840A (en) * 1989-08-03 1991-11-12 Merrell Dow Pharmaceuticals Anti-psychotic piperidylbenzimidazole compounds
US5116846A (en) * 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
TW197435B (pl) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
HUT71097A (en) * 1992-02-13 1995-11-28 Merrell Dow Pharma Piperidinyl-heterocyclic derivatives, containing sulphur pharmaceutical compositions comprising them and process for their preparation
CA2092112A1 (en) * 1992-03-23 1993-09-24 Nobuyoshi Iwata Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288563A1 (en) * 1986-09-30 1988-11-02 Eisai Co., Ltd. Cyclic amine derivatives
EP0351282A1 (fr) * 1988-07-12 1990-01-17 Synthelabo Dérivés de (hydroxy-1 pipéridinyl-2 alkyl)indolones-2, quinoléinones-2, benzo[b]azépinones-2, benzimidazolones-2 et quinazolinones-2, leur préparation et leur application en thérapeutique
EP0441517A2 (en) * 1990-02-08 1991-08-14 Pfizer Inc. Tricyclic amines as novel cholinesterase inhibitors

Also Published As

Publication number Publication date
NO308533B1 (no) 2000-09-25
EP0606248B1 (en) 2003-03-26
CZ290807B6 (cs) 2002-10-16
PT100917B (pt) 1999-07-30
ZA927589B (en) 1994-04-05
PL171693B1 (pl) 1997-06-30
JP2546785B2 (ja) 1996-10-23
ATE235490T1 (de) 2003-04-15
RO112868B1 (ro) 1998-01-30
CN1035615C (zh) 1997-08-13
WO1993007140A1 (en) 1993-04-15
SG52618A1 (en) 1998-09-28
MA22672A1 (fr) 1993-07-01
IL103274A (en) 1996-11-14
FI116939B (fi) 2006-04-13
CA2119647A1 (en) 1993-04-15
CA2119647C (en) 1998-08-04
NO941179L (no) 1994-03-30
PL171669B1 (en) 1997-06-30
FI941518A0 (fi) 1994-03-31
IL103274A0 (en) 1993-02-21
US6303633B1 (en) 2001-10-16
JPH06510788A (ja) 1994-12-01
DE9290112U1 (de) 1994-06-01
AP9200421A0 (en) 1992-10-31
UA41290C2 (uk) 2001-09-17
OA09895A (en) 1995-09-15
CZ78594A3 (en) 1995-07-12
HUT70544A (en) 1995-10-30
FI941518A (fi) 1994-03-31
EP0606248A1 (en) 1994-07-20
US5574046A (en) 1996-11-12
NO941179D0 (no) 1994-03-30
BG61727B1 (bg) 1998-04-30
RU2100357C1 (ru) 1997-12-27
ES2193137T3 (es) 2003-11-01
DK0606248T3 (da) 2003-06-23
MX9205678A (es) 1993-04-01
US20020049210A1 (en) 2002-04-25
BG98689A (bg) 1995-03-31
HU225049B1 (en) 2006-05-29
IS1745B (is) 2000-05-18
KR0170458B1 (ko) 1999-02-18
IS3919A (is) 1993-04-04
BR9206577A (pt) 1995-10-10
TW263504B (pl) 1995-11-21
DE69232976D1 (de) 2003-04-30
EG21481A (en) 2001-11-28
US6124321A (en) 2000-09-26
DE69232976T2 (de) 2003-10-02
UY23484A1 (es) 1993-03-11
PH31290A (en) 1998-07-06
AU667053B2 (en) 1996-03-07
CN1071166A (zh) 1993-04-21
NZ244601A (en) 1995-03-28
PL171984B1 (pl) 1997-07-31
HU9400952D0 (en) 1994-06-28
AU2519692A (en) 1993-05-03
PT100917A (pt) 1993-11-30

Similar Documents

Publication Publication Date Title
AP314A (en) "Heteroaryl amides as novel acetylcholinesterase inhibitors"
EP0316723B1 (en) 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments
EP0384349A1 (de) Substituierte Pyrrole
US5614518A (en) Morpholine derivatives as dopamine receptor subtype ligands
EP0532178B1 (en) Methanoanthracenes as dopamine antagonists
US5965574A (en) Heteroaryl amines as novel acetylcholinesterase inhibitors
CA2035805C (en) Tricyclic-cyclic amines as novel cholinesterase inhibitors
AU681601B2 (en) O-aryl ethers of morphinans
RU2156249C2 (ru) Соединения фенилиндола
CA1177830A (en) Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
IE67871B1 (en) Novel benzothiopyranylamines
US5428043A (en) Tricyclic-cyclic amines as novel cholinesterase inhibitors
HUT72610A (en) Process for producing cyclic amide derivatives and pharmaceutical compositions containing them